Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
FDMT

FDMT - 4D Molecular Therapeutics, Inc. Stock Price, Fair Value and News

23.25USD+0.31 (+1.35%)Market Closed

Market Summary

FDMT
USD23.25+0.31
Market Closed
1.35%

FDMT Stock Price

View Fullscreen

FDMT RSI Chart

FDMT Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-11.37

Price/Sales (Trailing)

57.37

Price/Free Cashflow

-14.97

FDMT Price/Sales (Trailing)

FDMT Profitability

Return on Equity

-17.41%

Return on Assets

-16.6%

Free Cashflow Yield

-6.68%

FDMT Fundamentals

FDMT Revenue

Rev. Growth (Yr)

3.9K%

Rev. Growth (Qtr)

8.3K%

FDMT Earnings

Earnings (TTM)

-104.6M

Earnings Growth (Yr)

-12.97%

Earnings Growth (Qtr)

-0.37%

Breaking Down FDMT Revenue

Last 7 days

-2.3%

Last 30 days

-7.6%

Last 90 days

-31.7%

Trailing 12 Months

27.7%

How does FDMT drawdown profile look like?

FDMT Financial Health

Current Ratio

32.65

FDMT Investor Care

Shares Dilution (1Y)

56.33%

Diluted EPS (TTM)

-2.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20232.2M2.3M22.0M20.7M
202217.3M2.8M2.0M3.1M
202114.7M15.8M16.9M18.0M
20208.6M10.3M12.0M13.6M
20190007.0M

Tracking the Latest Insider Buys and Sells of 4D Molecular Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 17, 2024
bizily scott
sold
-41,493
23.7106
-1,750
chief legal officer
Jun 17, 2024
bizily scott
acquired
13,295
7.59714
1,750
chief legal officer
May 16, 2024
bizily scott
acquired
26,590
7.59714
3,500
chief legal officer
May 16, 2024
bizily scott
sold
-89,082
25.452
-3,500
chief legal officer
Apr 16, 2024
bizily scott
sold
-45,045
25.74
-1,750
chief legal officer
Apr 16, 2024
bizily scott
acquired
13,295
7.59714
1,750
chief legal officer
Apr 01, 2024
bizily scott
sold
-259,102
31.78
-8,153
chief legal officer
Apr 01, 2024
bizily scott
acquired
102,224
12.5383
8,153
chief legal officer

1–10 of 50

Which funds bought or sold FDMT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-34.78
110,000
1,076,000
-%
May 29, 2024
Opaleye Management Inc.
added
11.55
4,713,550
10,963,800
2.39%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
93.48
205,187
305,187
0.04%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
12.64
395,255
907,691
-%
May 16, 2024
JANE STREET GROUP, LLC
added
15.75
423,692
940,221
-%
May 15, 2024
Laurion Capital Management LP
sold off
-100
-1,070,300
-
-%
May 15, 2024
SOROS FUND MANAGEMENT LLC
new
-
1,991,250
1,991,250
0.03%
May 15, 2024
LMR Partners LLP
new
-
15,532,800
15,532,800
0.16%
May 15, 2024
Point72 Asset Management, L.P.
sold off
-100
-8,428,560
-
-%
May 15, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
new
-
32.00
32.00
-%

1–10 of 41

Are Funds Buying or Selling FDMT?

Are funds buying FDMT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FDMT
No. of Funds

Unveiling 4D Molecular Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
kirn david
4.7%
2,033,069
SC 13G/A
Feb 14, 2024
deep track capital, lp
5.34%
2,284,372
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
8.9%
4,400,000
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
5.0%
2,132,411
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
9.7%
4,163,211
SC 13G/A
Feb 13, 2024
janus henderson group plc
7.2%
3,093,296
SC 13G/A
Jan 25, 2024
blackrock inc.
8.1%
3,464,587
SC 13G/A
Jan 08, 2024
viking global investors lp
9.9%
4,247,914
SC 13G/A
Jan 08, 2024
viking global investors lp
11.2%
4,787,914
SC 13G/A
Jun 05, 2023
ra capital management, l.p.
6.7%
2,789,721
SC 13G

Recent SEC filings of 4D Molecular Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 24, 2024
144
Notice of Insider Sale Intent
Jun 20, 2024
4
Insider Trading
Jun 07, 2024
424B5
Prospectus Filed
Jun 07, 2024
8-K
Current Report
May 24, 2024
8-K
Current Report
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading

Peers (Alternatives to 4D Molecular Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-17.75% 15.65%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
50.83% 15.66%
-84.89
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
12.78% -8.91%
78.71
6.54
13.74% 186.89%
14.3B
3.8B
11.22% 2.07%
19.2
3.8
8.58% 129.81%
MID-CAP
4.7B
524.1M
-5.39% -54.95%
-11.17
8.9
394.93% 39.61%
4.3B
107.9M
-17.68% 46.87%
-7.87
48.09
54.84% -28.31%
3.7B
251.0M
4.40% -10.91%
-12.58
14.85
73.58% -86.73%
3.4B
240.7M
9.49% -22.70%
-7.15
12.77
-1.03% -213.92%
2.6B
813.8M
4.41% -35.25%
-1.5K
3.22
56.43% 98.83%
2.0B
996.6M
-9.61% 109.10%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.09% 16.96%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-3.44% 394.54%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-27.55% 54.46%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-4.57% 211.94%
-0.78
7.61
-13.45% 69.54%

4D Molecular Therapeutics, Inc. News

Latest updates
Yahoo New Zealand News21 Jun 202405:03 pm
Defense World19 Jun 202410:38 am
TradingView4 months ago

4D Molecular Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue---20.000.000.001.001.000.001.000.001.0015.002.005.007.004.004.00-
Operating Expenses4.2%38.0037.0034.0032.0030.0030.0027.0029.0028.0025.0024.0022.0018.0019.0015.0019.0017.00-
  S&GA Expenses-2.9%10.0011.009.009.008.008.008.008.008.007.008.007.006.007.004.003.004.00-
  R&D Expenses-----------16.0015.0013.00-12.0016.0013.00-
Net Income-0.4%-32.40-32.28-10.26-29.62-28.68-27.38-25.69-28.09-26.34-25.08-22.24-7.59-16.41-20.55-7.83-15.15-13.16-
Net Income Margin-3.7%-5.05*-4.87*-4.36*-48.73*-49.76*-34.36*-53.32*-35.84*-4.71*-3.95*-3.94*-3.31*-4.07*-----
Free Cashflow-18.3%-29.80-25.20-1.58-22.87-28.92-23.31-22.98-21.97-29.96-26.93-18.36-16.94-16.01-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets85.3%63034036235324426228030332535324125527028858.00
  Current Assets80.6%53629732831820722123224724325616624926528353.00
    Cash Equivalents10.6%27624927623679.0052.0010811376.0015391.0024426027750.00
  Net PPE-3.3%19.0020.0021.0021.0022.0022.0022.0021.0018.0014.009.006.005.005.005.00
Liabilities-8.5%29.0032.0032.0027.0025.0031.0029.0030.0029.0034.0016.0014.0028.0032.0028.00
  Current Liabilities-13.4%16.0019.0018.0014.0011.0016.0014.0014.0012.0016.0011.0010.0014.0017.0013.00
Shareholder's Equity95.1%601308330325219231251273296319224241242256-
  Retained Earnings-7.8%-447-415-383-372-343-314-287-261-233-207-181-159-152-135-79.03
  Additional Paid-In Capital45.0%1,0487237126985625475405365315274064003953926.00
Shares Outstanding18.8%51.0043.0043.0042.0033.0033.0032.0032.0032.0032.0027.0027.0027.00--
Float----630---147---445---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-18.0%-29,088-24,650-1,171-22,065-27,906-22,214-21,017-19,904-23,550-21,836-15,721-16,205-15,372-17,499-13,371-6,169-13,870-
  Share Based Compensation1.0%5,9745,9134,5624,9694,2214,3464,5204,3223,9333,7313,9233,8162,3291,7171,1471,0371,083-
Cashflow From Investing-3839.8%-263,258-6,68229,98149,28843,130-35,77915,37157,468-54,110-32,291-139,010-737-642-508349-120-721-
Cashflow From Financing6595.3%318,8324,76210,557130,51910,9942,046460-50.00629116,1391,977820-847205,97890072,494-389-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

FDMT Income Statement

2024-03-31
Condensed Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Collaboration and license revenue$ 28$ 298
Operating expenses:  
Research and development27,87022,412
General and administrative10,2947,992
Total operating expenses38,16430,404
Loss from operations(38,136)(30,106)
Other income (expense):  
Interest income5,7451,443
Other expense, net(10)(19)
Total other income, net5,7351,424
Net loss$ (32,401)$ (28,682)
Net loss per share, basic$ (0.66)$ (0.88)
Net loss per share, diluted$ (0.66)$ (0.88)
Weighted-average shares outstanding used in computing net loss per share, basic49,271,98432,723,530
Weighted-average shares outstanding used in computing net loss per share, diluted49,271,98432,723,530

FDMT Balance Sheet

2024-03-31
Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 275,594$ 249,108
Marketable securities250,31739,124
Prepaid expenses and other current assets9,6788,356
Total current assets535,589296,588
Marketable securities, long-term62,94210,954
Property and equipment, net19,46420,126
Operating lease right-of-use assets, net11,11811,539
Other assets771684
Total assets629,884339,891
Current liabilities  
Accounts payable4,2173,515
Accrued and other current liabilities9,01312,014
Deferred revenue0273
Operating lease liabilities, current portion3,1733,149
Total current liabilities16,40318,951
Deferred revenue, net of current portion1,322972
Derivative liability369369
Operating lease liabilities, long-term portion10,99811,522
Other liabilities231248
Total liabilities29,32332,062
Commitments and contingencies (Note 9)
Stockholders’ equity  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value, 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 51,157,388 and 43,075,218 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively54
Additional paid-in-capital1,048,393723,136
Accumulated other comprehensive gain (loss)(109)16
Accumulated deficit(447,728)(415,327)
Total stockholders’ equity600,561307,829
Total liabilities and stockholders’ equity$ 629,884$ 339,891
FDMT
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
 CEO
 WEBSITE4dmoleculartherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES137

4D Molecular Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for 4D Molecular Therapeutics, Inc.? What does FDMT stand for in stocks?

FDMT is the stock ticker symbol of 4D Molecular Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 4D Molecular Therapeutics, Inc. (FDMT)?

As of Mon Jun 24 2024, market cap of 4D Molecular Therapeutics, Inc. is 1.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FDMT stock?

You can check FDMT's fair value in chart for subscribers.

What is the fair value of FDMT stock?

You can check FDMT's fair value in chart for subscribers. The fair value of 4D Molecular Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 4D Molecular Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FDMT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 4D Molecular Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether FDMT is over valued or under valued. Whether 4D Molecular Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact 4D Molecular Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FDMT.

What is 4D Molecular Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jun 24 2024, FDMT's PE ratio (Price to Earnings) is -11.37 and Price to Sales (PS) ratio is 57.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FDMT PE ratio will change depending on the future growth rate expectations of investors.